Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Sales of Investments

Cash received from selling or redeeming investments.

Cerus CorporationNASDAQ: CERS

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments growth accelerates

Q1 FY2026 sales of investments of $18.5M rose 168.7% year over year, ahead of the +17.6% change in trailing-twelve-month sales of investments. Sequentially, it rose 50.7% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.

Context

  • Sales of investments amounted to 18.3% of revenue in FY2025, down 2.6 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +168.7% holds above the trailing-twelve-month pace of +17.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.5M+50.7% QoQ
Last fiscal yearDec 2025
$37.68M+0.0% YoY
LTMMar 2026
$49.3M+17.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+168.7%——
1 year+0.0%——
3-year CAGR-2.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
37.68M USD
Year-over-year change
+0.0%
4-year CAGR
-13.0%

Sales of Investments vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Sales of investments amounts to 22.1% of revenue for CERS, versus a peer median of 0.0%.
CERS Competitors
Sales of Investments for CERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERSCerus CorporationLTM Mar 2026$49.3M USD+17.6%-2.1%22.1%
GRFSGrifols, S.A.LTM Jun 2026€0 EUR——0.0%
HAEHaemonetics CorporationLTM Jun 2026$0 USD——0.0%
ADMAADMA Biologics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding CERS) ———0.0%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.38M)(42.83M)(37.49M)(20.96M)(15.63M)
Depreciation & Amortization3.15M2.98M2.6M1.86M1.86M
Deferred Income Tax462K0000
Stock-Based Compensation23.57M24.46M20.27M22.87M22.87M
Change in Working Capital(9.4M)(16.05M)(32.04M)5.23M(6.83M)
Accounts Receivables(4.22M)(9.2M)(1.1M)5.5M(396K)
Inventory(19.61M)(1.77M)(14.95M)7.03M(14.68M)
Accounts Payables12.2M(4.91M)(7.34M)(1.48M)5.73M
Other Working Capital2.22M(179K)(8.65M)(5.83M)2.52M
Other Non-Cash Items2.67M5.82M3.49M2.37M9.09M
Operating Cash Flow(33.92M)(25.62M)(43.17M)11.36M11.36M
Capital Expenditures(910K)(2M)(4.6M)(2.84M)(2.84M)
Acquisitions (Net)910K(10.46M)000
Purchases of Investments(52.07M)(29.64M)(2.49M)(42.98M)(42.98M)
Sales of Investments65.66M40.1M15.71M37.68M37.68M
Other Investing Activities(910K)10.46M000
Investing Cash Flow12.69M8.46M8.62M(8.13M)(8.13M)
Debt Repayment21.18M212K9.92M4.3M(329K)
Common Stock Issued2.74M000560K
Common Stock Repurchased0(104K)(175K)00
Dividends Paid00000
Other Financing Activities10.37M4.08M925K667K4.73M
Financing Cash Flow34.29M4.19M10.67M4.96M4.96M
Effect of Forex Changes(919K)(727K)(128K)(191K)(191K)
Net Change in Cash12.14M(13.69M)(24M)8M8M
Free Cash Flow(34.83M)(27.62M)(47.77M)8.52M8.52M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.